Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154323
Status:
COMPLETED
Last Update Posted:
2023-12-14
First Post:
2005-09-08
Brief Title:
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mgDay as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Multi-center Randomized Double-blind Parallel Group Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine po300-1200 mgDay as Adjuvant Therapy in the Bipolar Disorder I or II Treatment
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania grandiose delusions and suicidality This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with bipolar disorder type I or II
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None